Monday, May 27, 2013

Drug delivery in Cancer



Cancer is an unanswerable question for researchers around the world from many decades. Exploring wide areas of biology, medicine and interdisciplinary fields like nanotechnology is going on to find a suitable molecule to kill cancer. The prescription of drugs (chemotherapy) to cancer patients by physicians across the globe after tumor removal is the current treatment modality. So the drugs play an important role in the treatment of cancer. The effectiveness of the drugs is limited while the side effects are more. But patients, as there is no other go, are ready to take these drugs.


From the last decade, the advent of nanotechnology in the delivery of medicine has paved the way for a new field called “Drug Delivery”. The main objective of this field is to develop various nanoformulation (a drug loaded nanocarrier) that is targeted to the specific diseased site, stay for a longer time in the body and minimizing side effects. Not every nanoformulation will fulfill all these three, but most of them will.


A recent development from Mc Neil’s Lab, part of the federally funded research and development center operated by SAIC-Frederick for the National Cancer Institute, worked with a drug company to reformulate TNF-alpha by coupling it with gold nanoparticles. Using the nanotechnology-enhanced protein, it appears possible to safely inject up to three times the amount that had been lethal with previous versions. The modified drug has been through a Phase 1 clinical trial and is entering Phase 2[1].
In future we can expect much more will come from many labs around the world and hope for a cancer free society.

[1] courtesy from Science daily, New Delivery for Cancer Drugs,May 7, 2013.